Use of strains of lactobacillus and by-products thereof for inhibiting formation of blood vessels

Abstract

A lactic composition containing at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus casei and a mixture of Lactobacillus acidophilus and Lactobacillus casei , and a whole broth of the bacterial strain or the mixture of the bacterial strains, is useful for the prevention or treatment of disorders which are angiogenesis dependant. Both the lactic composition and its supernatant can be used for prevention or treatment of angiogenesis dependant disorders. The supernatant of the lactic composition exhibits antiangiogenic properties.

1 . A supernatant obtained from a lactic composition comprising  Lactobacillus acidophilus  strain I-1492 deposited at the CNCM and  Lactobacillus casei  or a whole broth of each of said bacterial strain or a mixture thereof. 
     
     
         2 . (canceled) 
     
     
         3 . The supernatant of  claim 1 , characterized in that it is obtained from a lactic composition comprising at least 500 millions per gram of a population of living and active micro-organisms of the  Lactobacillus acidophilus  strains after 90 days under refrigeration, where at least 380 millions per gram are micro-organisms of the  Lactobacillus acidophilus  CNCM I-1492 strain. 
     
     
         4 . The supernatant of  claim 3 , characterized in that it is obtained from a lactic composition further comprising fermented milk proteins or fermented soy proteins. 
     
     
         5 . The supernatant  claim 1 , characterized in that said supernatant exhibits antiangiogenic properties. 
     
     
         6 . The supernatant according to  claim 5 , characterized in that said supernatant is concentrated. 
     
     
         7 . The supernatant according to  claim 5 , characterized in that said supernatant is 10× concentrated. 
     
     
         8 . The supernatant according to  claim 1 , characterized in that it comprises molecules of a size larger than 5000 kDa. 
     
     
         9 - 18 . (canceled) 
     
     
         19 . A method for prevention or treatment of an angiogenesis dependant disorder, the method comprising the step of administering to a mammal an effective amount of a supernatant obtained from a lactic composition comprising  Lactobacillus acidophilus  strain I-1492 deposited at the CNCM,  Lactobacillus casei , or a whole broth of each of said bacterial strain or a mixture thereof. 
     
     
         20 . The method according to  claim 19 , wherein said mammal is a human being. 
     
     
         21 . The method according to  claim 19 , wherein said disorder is selected from the group consisting of retinopathy, infantile haemangioma, rheumatoid arthritis, psoriasis, duodenal ulcers, post-angioplasty restenosis and tumour growth. 
     
     
         22 . The method according to  claim 21 , wherein said disorder is tumour growth. 
     
     
         23 . The method according to  claim 19 , wherein said administration is oral administration. 
     
     
         24 . The method of  claim 19 , wherein the supernatant is obtained by a process comprising the steps of:
 a. resuspending  Lactobacillus acidophilus  strain I-1492 deposited at the CNCM an  Lactobacillus casei  in a suitable medium to get a suspension;   b. incubating the suspension;   c. obtaining a liquid; and   d. filtering said liquid to obtain the supernatant.   
     
     
         25 . The method according to  claim 24 , characterized in that the suitable medium is complex MRS. 
     
     
         26 . The method according to  claim 24 , characterized in that the incubation of step d is at 37° C. 
     
     
         27 . The method according to  claim 24 , characterized in that the centrifugation is at 1000×g for 15 min. 
     
     
         28 . The method according to  claim 24 , characterized in that the filtration occurs on a 0.45 μm filter then on a 0.22 μm filter. 
     
     
         29 - 31 . (canceled)